C4 Therapeutics Inc (CCCC) Stock Price, Quote & News

Company Profile

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 clinical trials targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting BR...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 231 0700

Website: www.c4therapeutics.com

Address:

490 Arsenal Way, Suite120, Watertown, United States

JuggernautRaider Feb. 2 at 7:15 PM

$CCCC $GERN $SLS are three crazily undervalued blood cancer biotechs 🏦 which should be added to the list? 🧐

1 · Reply

zawojak Jan. 31 at 11:42 AM

$TSLA add $CCCC to your portfolio for possible 300% in 2027

1 · Reply

monoksop Jan. 28 at 6:18 PM

$CCCC Small starter here.

0 · Reply

zawojak Jan. 28 at 3:54 PM

$CCCC buy the dip , good opportunity.

0 · Reply

JuggernautRaider Jan. 27 at 2:53 PM

$GERN buying shares to complement $CCCC & $SLS in my portfolio. The phase 3 ImpactMF data is a major binary event and will change the second line MF treatment paradigm if positive. $INCY should buy them regardless but if its positive GERN should get back to $5 quickly later this year 🚀

0 · Reply

pleasemoney Jan. 26 at 8:53 PM

$IBRX - reduced position $CABA - reduced position $CCCC - new position $IFRX - new position $RZLV - new position please money!!!

1 · Reply

BioRich Jan. 26 at 4:39 AM

$XBI $XBI Top 12 for the week ahead (9-12) 9) $GPCR 10) $KYTX 11) $CCCC 12) $IBRX Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some (more) money. Cheers!

0 · Reply

zawojak Jan. 24 at 9:51 PM

$CCCC Gimme sign of life, be

0 · Reply

jerzypawlik Jan. 24 at 4:26 PM

$CCCC Just got out of CABA, NKTX and ALT. All my bid is now on CCCC and IFRX. I think these two will be the huge winners this year.

0 · Reply

JuggernautRaider Jan. 24 at 12:40 PM

$GERN looking very oversold ahead of its potential game changing IMPACT myelofibrosis overall survival readout later in 2026 🧐 FYI to my fellow $SLS and $CCCC investors looking for another nice hematology/oncology investment that is CHEAP 🚀

0 · Reply

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jan 14, 2026, 7:00 AM EST - 20 days ago

C4 Therapeutics Outlines Strategic Milestones to Advance Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader and Discovery Strategy Focused on Novel Targets in Clinically Validated Pathways

Nov 26, 2025, 6:27 AM EST - 2 months ago

Pipeline Momentum Drives C4 Therapeutics Despite Q3 EPS Miss

Nov 25, 2025, 7:00 AM EST - 2 months ago

C4 Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference

Nov 12, 2025, 10:16 AM EST - 2 months ago

Wasatch Ultra Growth Fund Q3 2025 Top Contributors And Detractors

CWST ESPR INSP MNDY SITM

Nov 6, 2025, 7:00 AM EST - 3 months ago

C4 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Oct 16, 2025, 7:08 AM EDT - 3 months ago

C4 Therapeutics Announces Pricing of $125 Million Underwritten Offering

$C4 Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Pfizer for the Combination of Cemsidomide and Elranatamab for the Treatment of Relapsed/Refractory Multiple Myeloma$

Oct 1, 2025, 7:00 AM EDT - 4 months ago

C4 Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Pfizer for the Combination of Cemsidomide and Elranatamab for the Treatment of Relapsed/Refractory Multiple Myeloma

Sep 22, 2025, 5:23 AM EDT - 4 months ago

C4 Therapeutics, Inc. - Special Call

Sep 20, 2025, 11:00 AM EDT - 4 months ago

C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the International Myeloma Society Annual Meeting

Sep 4, 2025, 7:00 AM EDT - 5 months ago

C4 Therapeutics Highlights Recent Achievement in Biogen Collaboration

Sep 3, 2025, 7:00 AM EDT - 5 months ago

C4 Therapeutics to Present Data from the Phase 1 Trial of Cemsidomide in Multiple Myeloma at the International Myeloma Society (IMS) Annual Meeting

Aug 7, 2025, 7:00 AM EDT - 6 months ago

C4 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Jun 16, 2025, 1:50 PM EDT - 8 months ago

C4 Therapeutics: An Entry Point If There's Ever Going To Be One

May 7, 2025, 7:00 AM EDT - 9 months ago

C4 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

Feb 27, 2025, 7:00 AM EST - 1 year ago

C4 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Feb 24, 2025, 7:00 AM EST - 1 year ago

C4 Therapeutics to Participate in Upcoming March Investor Conferences

Dec 8, 2024, 12:30 PM EST - 1 year ago

C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader

Nov 20, 2024, 7:00 AM EST - 1 year ago

C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors

Oct 15, 2024, 4:01 PM EDT - 1 year ago

C4 Therapeutics Appoints Paige Mahaney, Ph.D., as Chief Scientific Officer and Announces Retirement of Stewart Fisher, Ph.D.

Oct 9, 2024, 7:00 AM EDT - 1 year ago

C4 Therapeutics Announces Presentations and Participation in 7th Annual Targeted Protein Degradation & Induced Proximity Summit

Sep 13, 2024, 10:00 AM EDT - 1 year ago

C4 Therapeutics Presents Monotherapy Data Demonstrating Proof of Mechanism and Early Evidence of Proof of Concept From Ongoing CFT1946 Phase 1 Trial in BRAF V600 Mutant Solid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024

Sep 8, 2024, 6:05 PM EDT - 1 year ago

C4 Therapeutics to Present Preliminary CFT1946 Monotherapy Phase 1 Clinical Data at the European Society for Medical Oncology (ESMO) Congress 2024

Sep 3, 2024, 7:00 AM EDT - 1 year ago

C4 Therapeutics Appoints Veteran Biotechnology Leader Stephen Fawell, Ph.D. to Board of Directors

Aug 29, 2024, 7:00 AM EDT - 1 year ago

C4 Therapeutics to Participate in Upcoming September Investor Conferences

Aug 1, 2024, 7:00 AM EDT - 1 year ago

C4 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Jul 16, 2024, 4:01 PM EDT - 1 year ago

C4 Therapeutics to Present Preliminary Monotherapy Data from the Ongoing Phase 1 Trial of CFT1946 as a Mini Oral Presentation at the ESMO Congress 2024

Jul 8, 2024, 7:00 AM EDT - 1 year ago

C4 Therapeutics to Participate in the Virtual UBS Targeted Protein Degradation Day

Jun 10, 2024, 7:00 AM EDT - 1 year ago

C4 Therapeutics Appoints Ron Cooper as Chairman of the Board of Directors

May 8, 2024, 7:00 AM EDT - 1 year ago

C4 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

Apr 9, 2024, 7:00 AM EDT - 1 year ago

C4 Therapeutics to Participate in the Stifel 2024 Targeted Oncology Forum

Apr 8, 2024, 8:00 AM EDT - 1 year ago

C4 Therapeutics Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024

Mar 5, 2024, 4:30 PM EST - 2 years ago

C4 Therapeutics to Present New Preclinical Data on Highly Selective Orally Bioavailable BiDAC™ Degraders at the American Association for Cancer Research Annual Meeting 2024

Mar 4, 2024, 7:00 AM EST - 2 years ago

C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic Proteins

Feb 22, 2024, 7:00 AM EST - 2 years ago

C4 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

Jan 9, 2024, 4:01 PM EST - 2 years ago

C4 Therapeutics Announces 2024 Priorities and Extended Cash Runway to Advance Portfolio of Targeted Protein Degradation Medicines

Jan 4, 2024, 4:01 PM EST - 2 years ago

C4 Therapeutics Announces Closing of $25 Million Equity Investment by Betta Pharmaceuticals

Jan 4, 2024, 7:00 AM EST - 2 years ago

C4 Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

$C4 Therapeutics Announces Positive Data from CFT7455 Phase 1 Trial in Relapsed/Refractory Multiple Myeloma$

Dec 12, 2023, 4:01 PM EST - 2 years ago

C4 Therapeutics Announces Positive Data from CFT7455 Phase 1 Trial in Relapsed/Refractory Multiple Myeloma

Dec 12, 2023, 7:00 AM EST - 2 years ago

C4 Therapeutics Announces License and Research Collaboration with Merck to Discover and Develop Degrader-Antibody Conjugates (DACs)

$C4 Therapeutics to Host Webcast to Present New Dose Escalation Data from CFT7455 Phase 1 Study in Relapsed/Refractory Multiple Myeloma$

Nov 28, 2023, 7:00 AM EST - 2 years ago

C4 Therapeutics to Host Webcast to Present New Dose Escalation Data from CFT7455 Phase 1 Study in Relapsed/Refractory Multiple Myeloma

Nov 20, 2023, 7:00 AM EST - 2 years ago

C4 Therapeutics Strengthens Board of Directors with Owen Hughes Appointment

Nov 1, 2023, 7:00 AM EDT - 2 years ago

C4 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights

Oct 11, 2023, 7:00 AM EDT - 2 years ago

C4 Therapeutics Announces Upcoming Data Presentations for CFT8634, an Orally Bioavailable BiDAC™ Degrader in Development for Synovial Sarcoma and SMARCB1-Null Tumors, and CFT7455, an Orally Bioavailable MonoDAC™ Degrader in Development for Multiple Myelom

Sep 5, 2023, 4:01 PM EDT - 2 years ago

C4 Therapeutics Announces Chief Financial Officer Succession

Aug 8, 2023, 7:00 AM EDT - 2 years ago

C4 Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights

Jul 15, 2023, 1:58 AM EDT - 2 years ago

C4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jul 5, 2023, 7:00 AM EDT - 2 years ago

C4 Therapeutics Announces FDA Clearance of Investigational New Drug Application for CFT8919, an Orally Bioavailable BiDAC™ Degrader Targeting EGFR L858R for Non-Small Cell Lung Cancer

Jun 20, 2023, 7:00 AM EDT - 2 years ago

C4 Therapeutics Appoints Leonard Reyno, M.D., as Chief Medical Officer

May 30, 2023, 7:00 AM EDT - 2 years ago

C4 Therapeutics and Betta Pharmaceuticals Announce Exclusive Licensing Agreement for the Development and Commercialization in Greater China of CFT8919, an Orally Bioavailable BiDAC™ Degrader of EGFR L858R for NSCLC

JuggernautRaider Feb. 2 at 7:15 PM

$CCCC $GERN $SLS are three crazily undervalued blood cancer biotechs 🏦 which should be added to the list? 🧐

1 · Reply

zawojak Jan. 31 at 11:42 AM

$TSLA add $CCCC to your portfolio for possible 300% in 2027

1 · Reply

monoksop Jan. 28 at 6:18 PM

$CCCC Small starter here.

0 · Reply

zawojak Jan. 28 at 3:54 PM

$CCCC buy the dip , good opportunity.

0 · Reply

JuggernautRaider Jan. 27 at 2:53 PM

0 · Reply

pleasemoney Jan. 26 at 8:53 PM

$IBRX - reduced position $CABA - reduced position $CCCC - new position $IFRX - new position $RZLV - new position please money!!!

1 · Reply

BioRich Jan. 26 at 4:39 AM

0 · Reply

zawojak Jan. 24 at 9:51 PM

$CCCC Gimme sign of life, be

0 · Reply

jerzypawlik Jan. 24 at 4:26 PM

$CCCC Just got out of CABA, NKTX and ALT. All my bid is now on CCCC and IFRX. I think these two will be the huge winners this year.

0 · Reply

JuggernautRaider Jan. 24 at 12:40 PM

0 · Reply

zawojak Jan. 23 at 10:10 PM

$CCCC $6 in 2027, keep buying below $2.10 accumulate for a year. Big news 2027/2028.

0 · Reply

__ceezzz__ Jan. 23 at 7:12 PM

$CCCC Breakout incoming???

0 · Reply

jerzypawlik Jan. 23 at 1:37 AM

$CCCC this will run to $10 or higher this year. When they start releasing new data, this will go ballistic.

1 · Reply

zawojak Jan. 22 at 10:24 PM

$CCCC Run to $7 but more likely in early 2027

0 · Reply

JuggernautRaider Jan. 22 at 3:05 PM

$TNXP $IMRX $CCCC $ALT LFG 🚀

0 · Reply

Xanderzzzzzzz Jan. 21 at 7:12 PM

$CCCC

0 · Reply

JuggernautRaider Jan. 20 at 3:45 PM

Eh you didn’t ask nicely! Long $SLS $IMRX $CCCC and of course $NUVB ! Good day to you sir, I will post how I damn well please 🫡

1 · Reply

JuggernautRaider Jan. 18 at 11:35 PM

Well we agree on $TLSA $SLS $CCCC and other biotech stocks so I’m glad you’re not one of of the many StockTwits Trolls or shorts. I’m holding ALT long until convinced otherwise and while we agree on other criminally undervalued biopharma picks… let’s find some peace here, eh? ☮️ and if you think CADL is hot (and wasn’t their pancreatic cancer trial delayed??)… wait until you read up on $IMRX . They have a MEK inhibitor that looks like it can pair up with either FOLFIRINOX or Abraxane + gem in frontline PDAC to greatly improve overall survival in one of the deadliest cancers. Much like NUVB and SLS i wish I had bought every share I could when it was < $2. C’est la vie 🤷‍♂️ Please feel free to share where you saw that ALT is intentionally withholding data because it doesn’t make sense. Garg had many faults but pemvi was not one of them 💪

2 · Reply

JuggernautRaider Jan. 18 at 9:31 PM

$SNDX $CCCC $SLS if you love hematology / oncology biopharmas then C4 & SELLAS are must owns @Night_Owl_Biotech . I think that Syndax has peaked - it is more likely to be bought than KURA, but it’s also likely to underperform its launches. Syndax should have already been bought. If a buyout hasn’t happened by now and SNDX being bought is the main thesis for owning it, then I advise you all sell and diversify. Metzger is a much less impressive CEO than $NUVB ’s Hung, whom I trust to find another Ibtrozi type deal (he found a best in class ROS1 inhibitor for $250M… what else can he dig up?) 🧐

1 · Reply

JuggernautRaider Jan. 17 at 9:51 PM

$ALT $CCCC $IMRX $SLS four incredible biopharma stocks under $5 🚀

1 · Reply

zawojak Jan. 17 at 7:44 AM

$CCCC insider sold some shares yesterday.

0 · Reply

Ark11 Jan. 16 at 5:47 PM

$IBRX ---> $CCCC https://finance.yahoo.com/news/c4-therapeutics-cccc-one-best-161311736.html

0 · Reply

Market Cap	184.14M
Revenue (ttm)	35.58M
Net Income (ttm)	-105.32M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-296.01%
Debt to Equity Ratio	0.00

Volume	1,389,100
Avg Vol	1,647,646
Day's Range	N/A - N/A
Shares Out	96.91M
Stochastic %K	45%
Beta	2.93
Analysts	Strong Sell
Price Target	$9.86